1. Improving Appropriate Access to PCSK9 Inhibitors

2. Program Goals

3. 2017 NLA Recommendations on the Use of PCSK9 Inhibitors

4. 2017 AACE Guidelines for the Management of Dyslipidemia

5. 2017 Updated ACC Consensus Document on Role of Non-Statin Therapies for LDL-C Lowering

6. PCSK9 Trials: ODYSSEY and FOURIER

7. PCSK9 Inhibitors in Homozygous FH

8. FOURIER: Cardiovascular Outcomes

9. FH Foundation: Access to Nonstatin LLTs in Patients at High-Risk of ASCVD or With ASCVD

10. Access to PCSK9 Inhibitors

11. Barriers in Identifying the Patient: Prescribing Indication

12. Access to PCSK9 Inhibitors

13. Interprofessional Care Team

14. Barrier Studies and Recommendations

15. Abbreviations

16. Abbreviations (cont)